Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: In vitro and in vivo study

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 1, 2013, Pages 94-104

  Sinha, Biswadip ^a,b   Mukherjee, Biswajit ^a   Pattnaik, Gurudutta ^a  

^a JADAVPUR UNIVERSITY   (India)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Dry powder inhaler; Poly lactide co glycolide (PLGA); Porous nanoparticles; Pulmonary delivery; Voriconazole

Indexed keywords

DRY-POWDER INHALER; POLY-LACTIDE-CO-GLYCOLIDE; POROUS NANOPARTICLES; PULMONARY DELIVERY; VORICONAZOLE;

EMULSIFICATION; POROUS MATERIALS; TISSUE; ZETA POTENTIAL;

NANOPARTICLES;

POLYGLACTIN; POLYLACTIDE; VORICONAZOLE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOEMULSION; NONHUMAN; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTIFUNGAL AGENTS; DRUG CARRIERS; FEMALE; LACTIC ACID; LUNG; MALE; MICE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYGLYCOLIC ACID; PYRIMIDINES; TRIAZOLES;

MURINAE;

EID: 84871405176     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.04.005     Document Type: Article

References (28)

1. Lombry C., Bosquillon C., Preat V., Vanbever R. Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. J Control Release 2002, 83:331-341.
2. Shoyele S., Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 2006, 314:1-8.
3. Hindi K., Ditto A., Panzner M., Medvetz D., Han D., Hovis C., et al. The antimicrobial efficacy of sustained release silver-carbene complex-loaded l-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials 2009, 30:3771-3779.
4. Amaral A., Bocca A., Ribeiro A., Nunes J., Peixoto D., Simioni A., et al. Amphotericin B in poly(lactic-co-glycolic acid)(PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J Antimicrob Chemother 2009, 63:526-533.
5. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., Prasad B. Poly(d, l-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003, 52:981-986.
6. Sanati H., Belanger P., Fratti R., Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997, 41:2492-2496.
7. Peng H., Liu X., Lv G., Sun B., Kong Q., Zhai D., et al. Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy. Int J Pharm 2008, 352:29-35.
8. Arnold M., Gorman E., Schieber L., Munson E., Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. JControl Release 2007, 121:100-109.
9. Healy A., McDonald B., Tajber L., Corrigan O. Characterisation of excipient-free nanoporous microparticles (NPMPs) of bendroflumethiazide. Eur J Pharm Biopharm 2008, 69:1182-1186.
10. Naikwade S., Bajaj A., Gurav P., Gatne M., Singh Soni P. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSci Tech 2009, 10:993-1012.
11. Lamprecht A., Ubrich N., Hombreiro Pérez M., Lehr C.M., Hoffman M., Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 1999, 184:97-105.
12. Ueda M., Kreuter J. Optimization of the preparation of loperamide-loaded poly(l-lactide) nanoparticles by high pressure emulsification-solvent evaporation. J Microencapsul 1997, 14:593-605.
13. Sahana B., Santra K., Basu S., Mukherjee B. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomed 2010, 5:621-630.
14. Sinha B., Mukherjee B. Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model. Drug Dev Ind Pharm 2012, 38:171-179.
15. Balaxi M., Nikolakakis I., Malamataris S. Preparation of porous microcrystalline cellulose pellets by freeze-drying: effects of wetting liquid and initial freezing conditions. J Pharm Sci 2010, 99:2104-2113.
16. Schugens C., Laruelle N., Nihant N., Grandfils C., Jerome R., Teyssie P. Effect of the emulsion stability on the morphology and porosity of semicrystalline poly l-lactide microparticles prepared by w/o/w double emulsion-evaporation. J Control Release 1994, 32:161-176.
17. Viana M., Jouannin P., Pontier C., Chulia D. About pycnometric density measurements. Talanta 2002, 57:583-593.
18. Davies N.M., Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003, 255:175-187.
19. McConville J., Overhoff K., Sinswat P., Vaughn J., Frei B., Burgess D., et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006, 23:901-911.
20. Holt J. MMAD and GSD Calculator for Andersen Cascade Impactors (ACI) [Internet] 2010 [cited 2010 Sep 1]. Available from. http://www.mmadcalculator.com/andersen-impactor-mmad.html.
21. Werner M., Chott A., Fabiano A., Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000, 24:1016-1019.
22. Fox C.H., Johnson F.B., Whiting J., Roller P.P. Formaldehyde fixation. JHistochem Cytochem 1985, 33:845-853.
23. Mikos A.G., Sarakinos G., Leite S.M., Vacant J.P., Langer R. Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials 1993, 14:323-330.
24. Xiang-Gen W., Li-Na Y., Meng X., Hao-Ran J. Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by Aspergillus fumigatus. J Pharm Sci 2011, 100:1745-1759.
25. Gupta H., Aqil M., Khar R.K., Ali A., Bhatnagar A., Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomed Nanotechnol. 2010, 6:324-333.
26. Ma X., Bouchard D. Formation of aqueous suspensions of fullerenes. Environ Sci Technol 2008, 43:330-336.
27. Meißner T., Potthoff A., Richter V. Suspension characterization as important key for toxicological investigations. J Phys Conf Ser 2009, 170:012012.
28. Tolman J., Nelson N., Son Y., Bosselmann S., Wiederhold N., Peters J., et al. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm 2009, 72:199-205.